Allarity Therapeutics Secures $2.5M Through Private Placement

An announcement from Allarity Therapeutics ( (ALLR) ) is now available.

On September 22, 2025, Allarity Therapeutics entered into a Securities Purchase Agreement with an accredited investor to sell shares and pre-funded warrants in a private placement, aiming to raise approximately $2.5 million initially. The agreement includes provisions for an additional $7.5 million investment within 90 days, impacting the company’s financial strategy and market positioning. Additionally, Allarity has committed to filing registration statements with the SEC to facilitate the resale of these securities, with penalties for registration failures, indicating a focus on compliance and investor relations.

The most recent analyst rating on (ALLR) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Allarity Therapeutics stock, see the ALLR Stock Forecast page.

Spark’s Take on ALLR Stock

According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.

Allarity Therapeutics’ overall stock score is low due to significant financial challenges, including no revenue and consistent operational losses. Technical analysis shows a bearish trend with neutral momentum indicators, while valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. These factors collectively suggest a high-risk investment with limited current appeal.

To see Spark’s full report on ALLR stock, click here.

More about Allarity Therapeutics

Allarity Therapeutics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of therapeutic products for cancer treatment. The company engages in private placement transactions to raise capital for its operations.

Average Trading Volume: 7,152,313

Technical Sentiment Signal: Sell

Current Market Cap: $22.51M

Learn more about ALLR stock on TipRanks’ Stock Analysis page.